Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

Recruiting

Phase 2

Phase 3

Buprenorphine & XR-NaltrexoneEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

Sponsor:

New York State Psychiatric Institute

Code:

NCT05011266

Conditions

Opioid-use Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Buprenorphine/naloxone

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-22. This information was provided to ClinicalTrials.gov by New York State Psychiatric Institute on 2024-12-20.